Krystal Biotech (NASDAQ: KRYS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.990 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Krystal Biotech (NASDAQ: KRYS) through any online brokerage.
Other companies in Krystal Biotech’s space includes: Twist Bioscience (NASDAQ:TWST), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Fate Therapeutics (NASDAQ:FATE) and Xencor (NASDAQ:XNCR).
The latest price target for Krystal Biotech (NASDAQ: KRYS) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 78.00 expecting KRYS to rise to within 12 months (a possible 6.25% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Krystal Biotech (NASDAQ: KRYS) is $73.41 last updated Today at July 6, 2022, 3:55 PM UTC.
There are no upcoming dividends for Krystal Biotech.
Krystal Biotech’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Krystal Biotech.
Krystal Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.